Article produced in partnership with Jeen Health and Spital Clinic
Genetic testing for cancer risk in women, much of its medical history, is only available through a referral that includes a GP, a clinical genetic panel and family history testing that meets certain risk factors.
The advent of directly accessible private tests has changed this significantly.
Women who historically would not have been eligible for NHS genetic testing under current conditions can now receive medical certificates cancer genetic testing through private providers, often without waiting months for a professional appointment.
Why Genetic Risk Matters for Women’s Cancers
Most breast and ovarian cancers are sudden, with no clear genetic component. However, genetic variants including BRCA1, BRCA2, PALB2 and CHEK2 greatly increase the lifetime risk of this cancer in those who carry it.
To follow Cancer Research UK information on cancer geneticsWomen with a BRCA1 pathogenic variant face a lifetime risk of breast cancer of about 70 to 80 percent, compared to about 12 percent in the general population.
Identifying these types before diagnosis allows for intensive monitoring, risk reduction measures and informed reproductive planning.
Who is at High Risk?
Current NHS guidelines for clinical genetic referrals are outlined NICE CG164 in familial breast cancer. These plans are based on the number and degree of affected relatives and the types of cancer in the family history.
Many women who may have a risk gene do not meet these criteria for transmission,
Private genetic testing removes the barrier to eligibility.
Any woman who wishes to understand her genetic cancer risk can get tested regardless of her family history, although the value of testing is greatest where there are clinical symptoms.
Genes Strongly Associated with Women’s Cancer Risk
- BRCA1 and BRCA2: the best-known genes for ovarian cancer, with high penetrance.
- PALB2: a moderate-risk gene for breast cancer, now being included in routine panels
- CHEK2: associated with a modest increase in breast cancer risk
- RAD51C and RAD51D: associated with a higher risk of ovarian cancer
- MLH1, MSH2, MSH6, PMS2: Lynch syndrome genes, associated with increased risk of colorectal, endometrial and ovarian cancer
Testing of these genes together provides a comprehensive assessment of genetic cancer risk across clinically important pathways.
How Testing Works: Home and Clinic Options
Genetic testing at home for genetic cancer risk is offered by companies that include Jeen Healthwhich provides a clinically validated panel test using a saliva or cheek sample collected at home.
Laboratory testing is performed by certified equipment and results are provided digitally. This procedure offers privacy and convenience and is ideal for women seeking an early risk assessment.
Clinical examination, available through providers such as Hospital Clinicit offers the benefit of face-to-face interviews as well as genetic results, allowing for current clinical status and referral where indicated.
For women who get good results, talking to doctors is very important.
Genetic Counseling: Before and After
Genetic testing is an important part of genetic cancer testing.
Before testing, a counselor can help clarify which genes are most important, what a positive or negative result might mean, and how the findings may affect family members.
After the test, counseling provides the clinical context necessary to correctly interpret the results and plan the next steps.
A positive result does not mean that cancer cannot be avoided. It means that the risk is high and that risk reduction strategies, such as increased surveillance, chemoprevention or preventive surgery, can be discussed with the appropriate specialists.
A negative result reduces the risk significantly but does not reduce it to zero, as not all types of genetic risk are captured by the same panel.
What Happens After a Good Result
Women diagnosed with a genetic predisposition are often referred to a specialized genetics clinic for a full family test.
The choice of system depends on the gene involved, the specific variant selected, and the individual’s personal and family history.
Options include improved monitoring with annual MRI and mammography, risk-reducing medications such as tamoxifen, or risk-reducing surgery.
For women who are considering pregnancy, the survey also provides advice on pre-goat genetic testing (PGT) and pregnancy testing.
Description: This article is for informational purposes only and does not constitute medical advice, diagnosis or treatment. The clinical guidance cited reflects NHS, NICE and RCOG standards published as of March 2026. Individual conditions vary; readers are advised to consult a qualified health care professional before acting on any information in this article. This article was created in collaboration with Jeen Health and Spital Clinic, which provided basic medical information for editing purposes. Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organization.
#Gynecological #cancer #screening #professional #private